摘要
骨质疏松性骨折后患者的治疗包括全身抗骨质疏松症治疗和局部抗骨质疏松性骨折治疗。理想的抗骨质疏松药物应既能治疗全身的骨质疏松症,又可促进局部骨质疏松性骨折的愈合。临床现在应用和在研的促骨形成药物(甲状旁腺素片段、锶盐、甲状旁腺素相关蛋白和骨硬化素抗体)在治疗骨质疏松症的同时,具有已被证明的或潜在的促骨折愈合作用。本文对促骨形成药物干预骨质疏松性骨折的临床研究进展进行综述。
The treatment after osteoporotic fracture include anti-osteoporotic medications and local treatment to improve fracture healing. The ideal anti-osteoporotic medications should enhanced fracture healings in addition to their anti-osteoporotic therapy effect. Anabolic anti-osteoporotic medications, such as parathyroid hormone （ PTH ）, strontium, PTHr P and sclerostin antibody, are demonstrated to have certain or potential effects in improving fracture healing. In this paper, the progression of anabolic medications on fracture healing are summarized.
作者
辛力
林华
XIN Li LIN Hua(Department of Orthopeadics, Affiliated Hospital of Xuzhou Medical University, Xuzhou 221003, Jiangsu, China Bone Disease Center, Affiliated Drum Tower Hospital of Medical School Nanfing University, Nanjing 210008, China)
出处
《中华骨质疏松和骨矿盐疾病杂志》
CSCD
2017年第1期72-78,共7页
Chinese Journal Of Osteoporosis And Bone Mineral Research
基金
江苏省社会发展基金(BE2011605)
徐州市科技项目基金(XZZD1329)
关键词
促骨形成药物
骨质疏松
骨折
fracture healing
osteoporosis
anabolic
medication
fragility fracture
